

Victoria Atkinson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11470333/publications.pdf>

Version: 2024-02-01

90
papers

16,413
citations

201385

27
h-index

64668

79
g-index

91
all docs

91
docs citations

91
times ranked

16123
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	13.9	4,795
2	Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1867-1876.	13.9	1,824
3	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	13.9	1,752
4	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	13.9	1,441
5	Adjuvant Dabrafenib plus Trametinib in Stage III <i>BRAF</i> -Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	13.9	1,192
6	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1248-1260.	5.1	832
7	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 672-681.	5.1	732
8	Adjuvant nivolumab versus ipilimumab in resected stage IIIA-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477.	5.1	330
9	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295
10	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	3.4	287
11	Dabrafenib, trametinib and pembrolizumab or placebo in <i>BRAF</i> -mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 941-946.	15.2	256
12	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	13.9	256
13	Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in <i>BRAF</i> -mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 936-940.	15.2	246
14	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600E-Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	0.8	226
15	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1202-1210.	5.1	211
16	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2017, 3, 1511.	3.4	131
17	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	0.8	119
18	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i> -mutant melanoma. , 2020, 8, e001806.		110

#	ARTICLE	IF	CITATIONS
19	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	1.3	97
20	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 358-372.	5.1	94
21	5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , 2021, 27, 5225-5235.	3.2	82
22	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020, 26, 1557-1563.	15.2	78
23	Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. <i>Lancet</i> , 2020, 8, e001681.		57
24	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9502-9502.	0.8	52
25	Acute Atrial Stretch Results in Conduction Slowing and Complex Signals at the Pulmonary Vein to Left Atrial Junction. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 1189-1197.	2.1	51
26	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 701-710.	5.1	50
27	Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9508-9508.	0.8	41
28	Recent advances in malignant melanoma. <i>Internal Medicine Journal</i> , 2017, 47, 1114-1121.	0.5	40
29	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9531-9531.	0.8	31
30	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	1.3	28
31	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). <i>Melanoma Research</i> , 2020, 30, 261-267.	0.6	27
32	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020, 26, 5086-5091.	3.2	27
33	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	2.9	27
34	First-In-Human Phase I Study of a Next-Generation, Oral, TGF β 2 Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6666-6676.	3.2	27
35	BRAF ^{V600E} Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy With or Without Trametinib. <i>JAMA Dermatology</i> , 2014, 150, 1079.	2.0	26
36	Preliminary findings from part 1 of COMBI-i: A phase III study of anti-PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 189-189.	0.8	26

#	ARTICLE	IF	CITATIONS
37	Human CD141 ⁺ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model. , 2021, 9, e001963.		25
38	Medical management of malignant melanoma. Australian Prescriber, 2015, 38, 74-78.	0.5	24
39	Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.. Journal of Clinical Oncology, 2021, 39, 9504-9504.	0.8	23
40	The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma. Melanoma Research, 2017, 27, 168-170.	0.6	23
41	Optimizing combination dabrafenib and trametinib therapy in BRAF mutation ⁺ positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 5-12.	0.7	22
42	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. Clinical Cancer Research, 2021, 27, 5280-5288.	3.2	21
43	Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.. Journal of Clinical Oncology, 2020, 38, 10000-10000.	0.8	21
44	Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. BMC Nephrology, 2020, 21, 391.	0.8	20
45	Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III <i>BRAF</i> ^{V600E} mutant melanoma: Five-year analysis of COMBI-AD.. Journal of Clinical Oncology, 2020, 38, 10001-10001.	0.8	20
46	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation ⁺ positive melanoma. British Journal of Cancer, 2018, 118, 777-784.	2.9	19
47	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer, 2021, 158, 156-168.	1.3	19
48	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APLus. European Journal of Cancer, 2022, 163, 79-87.	1.3	17
49	Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. European Journal of Cancer, 2021, 142, 10-17.	1.3	16
50	A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).. Journal of Clinical Oncology, 2019, 37, TPS9600-TPS9600.	0.8	16
51	Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 2020, 10, 17687.	1.6	14
52	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 2021, 153, 168-178.	1.3	14
53	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	1.8	12
54	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
56	Phase 1b study of PV-10 and anti-PD-1 in advanced cutaneous melanoma.. Journal of Clinical Oncology, 2019, 37, 9559-9559.	0.8	12
57	The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. European Journal of Cancer, 2020, 138, 68-76.	1.3	10
58	KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.. Journal of Clinical Oncology, 2017, 35, 9545-9545.	0.8	10
59	Implementing PROMS for elective surgery patients: feasibility, response rate, degree of recovery and patient acceptability. Journal of Patient-Reported Outcomes, 2022, 6, .	0.9	10
60	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III <i>BRAF</i>-mutant melanoma.. Journal of Clinical Oncology, 2018, 36, 9590-9590.	0.8	9
61	Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected <i>BRAF</i>-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.. Journal of Clinical Oncology, 2018, 36, 9591-9591.	0.8	8
62	The anti-â€œPD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced <i>BRAF</i> V600â€œ-mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.. Journal of Clinical Oncology, 2020, 38, 10028-10028.	0.8	8
63	Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation â€œ Authors' reply. Lancet Oncology, The, 2018, 19, e367.	5.1	7
64	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.. Journal of Clinical Oncology, 2021, 39, 9525-9525.	0.8	7
65	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. ANZ Journal of Surgery, 2021, 91, 3-13.	0.3	7
66	Effectiveness of dabrafenib in the treatment of patients with BRAF V600â€œ-mutated metastatic melanoma in a Named Patient Program. Melanoma Research, 2019, 29, 527-532.	0.6	6
67	Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis.. Journal of Clinical Oncology, 2020, 38, 10016-10016.	0.8	6
68	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers, 2022, 14, 2300.	1.7	6
69	Patient Judgement of Change with Elective Surgery Correlates with Patient Reported Outcomes and Quality of Life. Healthcare (Switzerland), 2022, 10, 999.	1.0	6
70	Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in <i>BRAF</i> ^{V600E/K}-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.. Journal of Clinical Oncology, 2022, 40, 9516-9516.	0.8	6
71	Protocol for implementation of the â€œAusPROMâ€œ™ recommendations for elective surgery patients: a mixed-methods cohort study. BMJ Open, 2021, 11, e049937.	0.8	5
72	Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 536-545.	0.9	5

#	ARTICLE	IF	CITATIONS
73	Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. <i>Current Oncology Reports</i> , 2022, 24, 1273-1280.	1.8	5
74	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 9500-9500.	0.8	4
75	Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). <i>Journal of Clinical Oncology</i> , 2017, 35, 9513-9513.	0.8	4
76	The changing paradigm of management in melanoma brain metastases. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 453-458.	0.7	3
77	Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C. <i>Journal of Clinical Oncology</i> , 2019, 37, 9514-9514.	0.8	3
78	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19.	0.3	3
79	A case of acute paraneoplastic neurological syndrome in BRAF mutant metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 425-428.	0.6	2
80	Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 9545-9545.	0.8	2
81	383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695. <i>Journal of Clinical Oncology</i> , 2021, 39, A417-A417.		2
82	Reply to "Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy". <i>British Journal of Cancer</i> , 2017, 116, e15-e15.	2.9	1
83	Reply to E. Hindi and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019, 37, 1356-1358.	0.8	1
84	Analysis of metastatic melanoma treated with immune checkpoint inhibitors and the rates of adverse events of colitis and hepatitis. <i>Journal of Clinical Oncology</i> , 2021, 39, e21591-e21591.	0.8	1
85	Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real-world study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1371-1379.	0.9	0
86	Hospital admissions and subsequent outcomes from immune-related adverse events. <i>Journal of Clinical Oncology</i> , 2021, 39, e21590-e21590.	0.8	0
87	Non-sclerosing large duct cholangitis secondary to checkpoint inhibition. <i>Internal Medicine Journal</i> , 2021, 51, 1758-1759.	0.5	0
88	In-Depth Characterisation of Real-World Advanced Melanoma Patients Receiving Immunotherapies and/or Targeted Therapies: A Case Series. <i>Cancers</i> , 2022, 14, 2801.	1.7	0
89	Utility and timeliness of somatic genetic testing for patients enrolled in the molecular screening and therapeutics (MoST) study at Princess Alexandra Hospital (PAH). <i>Journal of Clinical Oncology</i> , 2022, 40, e15039-e15039.	0.8	0
90	Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, e16033-e16033.	0.8	0